Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and PD-L1 are crucial cancer therapies.
• Colitis is a known adverse event associated with ICI therapy.
• Standard treatment involves immunosuppression with corticosteroids and anti-TNF agents.

Observation:

• A 69-year-old male developed severe colitis two weeks after anti-PD-L1 mAb (durvalumab) treatment.
• The patient's colitis was refractory to systemic corticosteroids, anti-TNF, and anti-integrin agents.
• The patient unfortunately died within one month of developing colitis.

Findings:

• This case highlights a rare instance of rapidly progressing and fatal ICI-induced colitis.
• Refractory colitis despite multiple immunosuppressive therapies indicates a severe clinical course.
• Early-onset severe ICI-induced colitis poses a significant treatment challenge.

Implications:

• Clinicians must maintain a high index of suspicion for early-onset, severe ICI-induced colitis.
• Urgent, optimized rescue measures are necessary for patients with refractory ICI-induced colitis.
• Further research into novel therapeutic strategies for severe ICI-induced colitis is warranted.